305 related articles for article (PubMed ID: 33408779)
1. YAP in pancreatic cancer: oncogenic role and therapeutic strategy.
Mao W; Mai J; Peng H; Wan J; Sun T
Theranostics; 2021; 11(4):1753-1762. PubMed ID: 33408779
[TBL] [Abstract][Full Text] [Related]
2. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
3. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma.
Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H
Front Oncol; 2021; 11():700315. PubMed ID: 34395269
[TBL] [Abstract][Full Text] [Related]
4. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops.
Eibl G; Rozengurt E
Semin Cancer Biol; 2019 Feb; 54():50-62. PubMed ID: 29079305
[TBL] [Abstract][Full Text] [Related]
5. YAP and AP-1 Cooperate to Initiate Pancreatic Cancer Development from Ductal Cells in Mice.
Park J; Eisenbarth D; Choi W; Kim H; Choi C; Lee D; Lim DS
Cancer Res; 2020 Nov; 80(21):4768-4779. PubMed ID: 32900774
[TBL] [Abstract][Full Text] [Related]
6. Role of the transcriptional coactivators YAP/TAZ in liver cancer.
Zhang S; Zhou D
Curr Opin Cell Biol; 2019 Dec; 61():64-71. PubMed ID: 31387016
[TBL] [Abstract][Full Text] [Related]
7. The Hippo Signaling Pathway in Pancreatic Cancer.
Ansari D; Ohlsson H; Althini C; Bauden M; Zhou Q; Hu D; Andersson R
Anticancer Res; 2019 Jul; 39(7):3317-3321. PubMed ID: 31262852
[TBL] [Abstract][Full Text] [Related]
8. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3.
Yang S; Zhang L; Purohit V; Shukla SK; Chen X; Yu F; Fu K; Chen Y; Solheim J; Singh PK; Song W; Dong J
Oncotarget; 2015 Nov; 6(34):36019-31. PubMed ID: 26440309
[TBL] [Abstract][Full Text] [Related]
9. Stiehopus japonieus acidic mucopolysaccharide inhibits the proliferation of pancreatic cancer SW1990 cells through Hippo-YAP pathway.
Li X; Liu Y; Zhang C; Niu Q; Wang H; Che C; Xie M; Zhou B; Xu Y; Zhang Q; Wu J; Tian Z
Oncotarget; 2017 Mar; 8(10):16356-16366. PubMed ID: 28099921
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
11. The MST4-MOB4 complex disrupts the MST1-MOB1 complex in the Hippo-YAP pathway and plays a pro-oncogenic role in pancreatic cancer.
Chen M; Zhang H; Shi Z; Li Y; Zhang X; Gao Z; Zhou L; Ma J; Xu Q; Guan J; Cheng Y; Jiao S; Zhou Z
J Biol Chem; 2018 Sep; 293(37):14455-14469. PubMed ID: 30072378
[TBL] [Abstract][Full Text] [Related]
12. lncRNA
Li N; Yang G; Luo L; Ling L; Wang X; Shi L; Lan J; Jia X; Zhang Q; Long Z; Liu J; Hu W; He Z; Liu H; Liu W; Zheng G
Clin Cancer Res; 2020 Apr; 26(7):1736-1748. PubMed ID: 31831555
[TBL] [Abstract][Full Text] [Related]
13. Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling.
Gopal U; Mowery Y; Young K; Pizzo SV
J Biol Chem; 2019 Sep; 294(38):13939-13952. PubMed ID: 31358620
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions.
Jiang Z; Zhou C; Cheng L; Yan B; Chen K; Chen X; Zong L; Lei J; Duan W; Xu Q; Li X; Wang Z; Ma Q; Ma J
J Exp Clin Cancer Res; 2018 Mar; 37(1):69. PubMed ID: 29587800
[TBL] [Abstract][Full Text] [Related]
15. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C
Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622
[TBL] [Abstract][Full Text] [Related]
16. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
17. Targeting YAP and Hippo signaling pathway in liver cancer.
Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
[TBL] [Abstract][Full Text] [Related]
18. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
19. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
20. YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis.
Wu BK; Mei SC; Chen EH; Zheng Y; Pan D
Nat Genet; 2022 Aug; 54(8):1202-1213. PubMed ID: 35835915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
